Drug Trial Radar · NCT07725822
An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Jul 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Modern Research Associates, PLLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label trial in subjects ≥12 years of age and older with chronic plaque psoriasis and moderate to severe nail psoriasis. Eligible participants will apply roflumilast 0.3% cream daily for 24 weeks to affected nails daily for the entire study duration and to psoriasis plaques daily until clear.
Conditions
- Chronic Plaque Psoriasis
- Nail Psoriasis
Interventions
Roflumilast 0.3% topical creamDrug
Roflumilast 0.3% topical cream QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Nail Psoriasis Severity Index (NAPSI)Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Modern Research Associates, PLLC
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.